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A patient on maintenance hemodialysis was infected with a recently discovered putative non-A to -E hepatitis virus
designated GB virus C (GBV-C) or hepatitis G virus (HGV) by transfusion. The viral isolate was recovered from the patient
soon after she turned positive for GBV-C/HGV RNA in serum (GSI85) and 8.4 years thereafter (GSI93), and the entire
nucleotide sequences were determined. They both had a genomic length of 9391 nucleotides with a defective C gene made
of only 42 nucleotides. Between GSI85 and GSI93, 31 (0.33%) nucleotides were different, which changed 5 (0.18%) of the
encoded 2842 amino acids. Thus, GBV-C/HGV was estimated to have a mutation rate of 3.9 1 1004 base substitutions per
site per year. Nucleotide conversions were distributed over subgenomic regions, except in the 5* untranslated region of
552 nucleotides and a defective short C gene, which were conserved in sequence. The change in the putative envelope
genes (E1 and E2) was no different from that in the entire genome with only 6 (0.35%) nucleotide substitutions among the
1730, just 1 of which induced an amino acid conversion. Taken along with the comparison of the two isolates with the
reported five GBV-C or HGV isolates, these results indicate that GBV-C/HGV would not have hypervariable regions and
would use a strategy for viral persistence that is different from immune escape. q 1997 Academic Press
INTRODUCTION bling Flaviviridae and are distantly related to HCV with
a sequence divergence too wide to be classified as ge-
The discovery of hepatitis C virus (HCV) has re-
notypes of HCV. GBV-C and HGV share 86% of nucleotide
vealed it to be the major etiologic agent of blood-
(nt) sequence and 96% of deduced amino acid (aa) se-
borne, acute as well as chronic, non-A, non-B hepatitis
quence, and therefore are considered to be the same
worldwide (Choo et al., 1989; Kuo et al., 1989). The
virus. Five genomes of GBV-C/HGV have been se-
exclusion of blood units with markers of HCV infection
quenced in full, including two from the United States, one
has decreased the risk of posttransfusion HCV infec-
from Africa, and two from Japan (Leary et al., 1996; Linnen
tion virtually to zero (Holland, 1996; Schreiber et al.,
et al., 1996; Okamoto et al., 1997). Very recently, another
1996). The recognition of HCV infection, however, has
GBV-C/HGV genome has been sequenced in its entirety
unearthed a category of acute and chronic hepatitis (Erker et al., 1996). They may be classified into three
without serological markers of known hepatitis vi- distinct genotypes provisionally designated G1, G2, and
ruses, and therefore is referred to as non-A to -E hepa- G3 (Okamoto et al., 1997). Muerhoff et al. (1996) also
titis (Alter and Bradley, 1995). have found evidence for three major groups of GBV-C/
Recently, putative agents responsible for non-A to -E HGV based on the sequence heterogeneity within a 5*-
hepatitis have been cloned independently by two groups terminal sequence of 600 bp.
of investigators and their sequences determined (Leary The five GBV-C/HGV genomes have a similarity in the
et al., 1996; Linnen et al., 1996; Simons et al., 1995). They nucleotide sequence of 86% which far exceeds that
are designated GB virus C (GBV-C) and hepatitis G virus of reported HCV genomes at 65% (Bukh et al., 1995;
(HGV). They both are a positive single-stranded RNA vi- Miyakawa et al., 1995; Simmonds, 1995). Therefore, GBV-
rus having sequence and genetic organization resem- C/HGV may have a mutation rate lower than the 1.4–1.9
1 1003 base substitutions per site per year reported for
The nucleotide sequence data reported in this article have been HCV (Ogata et al., 1991; Okamoto et al., 1992a). We have
deposited with the DDBJ, EMBL, and GenBank Databases under Acces- cloned and sequenced GBV-C/HGV isolates recovered
sion No. D87262 for the GSI85 isolate and D87263 for the GSI93 isolate.
from a patient on hemodialysis at an interval of 8.4 years1 To whom correspondence and reprint requests should be ad-
and compared them within the entire genome and sub-dressed at Immunology Division, Jichi Medical School, Minamikawachi-
Machi, Tochigi-Ken 329-04, Japan. Fax: (81) 285-44-1557. genomic regions.
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FIG. 1. Clinical course of a patient on maintenance hemodialysis who contracted infection with GB virus C/hepatitis G virus by transfusion.
Relative titers of GB virus C/hepatitis G virus and fluctuating levels of alanine aminotransferase (ALT) are shown. Triangles represent transfusions,
and arrows indicate blood samplings from which GSI85, GSI93, and GSI96 isolates were recovered.
MATERIALS AND METHODS anate and phenol (ISOGEN-LS from Nippon Gene Co,
Ltd., Tokyo, Japan) and dissolved in 5.3 ml of distilled
Serum samples
water pretreated with diethylpyrocarbonate. They were
heated at 707 for 1 min, chilled quickly on ice, convertedA patient (female, 45 years) with chronic renal failure
received transfusion with one unit of concentrated eryth- to cDNA, and tested for GBV-C/HGV RNA by PCR with
primers deduced from the 5* untranslated region (UTR)rocytes (recovered from 200 ml of blood) on March 28
and April 8 and then two units on May 16, 1985 [patient by the method described previously (Shimizu et al., 1996).
Serial 10-fold dilutions of extracted RNA were tested,14 reported by Masuko et al. (1996)]. She was negative
for GBV-C/HGV RNA in serum taken on March 26, and and the relative concentration of GBV-C/HGV RNA was
expressed by the reciprocal of the highest dilution infound to have turned positive on April 30 and remained
so thereafter (Fig. 1). She was found to be infected with which the viral RNA was detectable; it was converted to
represent the titer (10N) per milliliter.HCV on December 28, 1993, and seroconverted to anti-
body to HCV in February 1994. The antibody gradually
Determination of the genomic sequenceincreased to a high titer (absorbance in enzyme immuno-
of GBV-C/HGVassay 2.00) in May 1994 and thereafter. GBV-C/HGV
isolate in her serum taken on June 11, 1985, when the Nucleic acids extracted from 100 ml of serum were
viral RNA was increasing in titer, and that in the last dissolved in distilled RNase-free water and denatured at
serum harvested on November 16, 1993, before she 707 for 1–3 min. They were transcribed into cDNA with
turned positive for HCV RNA, were amplified by polymer- antisense primers and cloned reverse transcriptase of
ase chain reaction (PCR) to determine the entire nucleo- Molony murine leukemia virus (Superscript II; GIBCO
tide sequences. They were designated GSI85 and GSI93, BRL, Gaithersburg, MD). cDNA was heated at 957 for 15
respectively, representing two GBV-C/HGV isolates re- min and subjected to PCR with TaKaRa Ex Taq polymer-
covered from the patient with an interval of 8.4 years. ase (TaKaRa Biochemicals, Kyoto, Japan) for 35 cycles
Her alanine aminotransferase levels stayed within nor- (947, 30 sec; 557, 30 sec; 727, 45–150 sec [8 min in the
mal limits (45 U/L) through the 8.4 years, but were last cycle]). One-tenth of the product was amplified by a
elevated after she contracted HCV infection in parallel second PCR for 25–35 cycles under the same conditions.
with HCV RNA titers. The envelope genes of GBV-C/HGV Strategy of sequencing GBV-C/HGV is shown in Fig. 2.
(E1 and E2), as well as the hypervariable region (HVR) GSI85 was amplified in six domains (regions a to f) and
of HCV spanning 25 aa in the E2 gene (Hijikata et al., GSI93 in seven (c, d, and g to k). Either conserved or isolate-
1991; Ogata et al., 1991; Okamoto et al., 1992a; Weiner dependent sense and antisense primers were used to am-
et al., 1991), were sequenced and compared at an inter- plify regions b to e and h to j (sequences shown in the
val of 2.8 years. legend to Fig. 2), while a single-sided PCR method was
used to amplify the other regions. cDNAs corresponding to
Semiquantification of GBV-C/HGV RNA
the 5*-terminal sequences (regions a and g) were tailed
with dATP or dTTP homopolymer at the 3*-end by terminalTotal RNAs were extracted from serum (100 ml) using
the extraction reagent containing guanidinium isothiocy- deoxynucleotidyl transferase (Boehringer Mannheim, Mann-
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FIG. 2. The genomic organization and strategy for sequencing GSI85, GSI93, and GSI96 isolates. The nucleotide sequence was numbered from
the putative 5*-end, and the genomic organization was estimated from open reading frames recognized in the genomic sequence. Closed bars
represent cDNAs amplified by PCR with appropriate primers. They spanned a, nt 1–190; b, nt 130–2234; c, nt 2175–4436; d, nt 4279–6933; e, nt
6883–9296; f, nt 9044–9391; g, nt 1–151; h, nt 43–2234; i, nt 6883–9251; j, nt 9044–9351; k, nt 9281–9391; l, nt 338–1760; and m, nt 1493–2371.
Primers and their sequences for amplification of each genomic region were a, 166 (5*-AGG GAT CCG TCG ACA TCG AT-3*) and G111 (5*-CCY
TTW AGA CCC ACC TAT AGT-3*); b, G58 (5*-CAG GGT TGG TAG GTC GTA AAT CC-3*) and G82 (5*-GCC TCA GCC AGC TTC ATC AG-3*); c, G25
(5*-TCG CTG GTT GCT GCT GGA CTT TGT-3*) and G9 (5*-TCY TTG ATG ATD GAA CTG TC-3*); d, G8 (5*-TAT GGG CAT GGH ATH CCY CT-3*) and
G47 (5*-AGG CAT CTC TCG GCT ACT TCC ACA-3*); e, G137 (5*-ATG GAG GAC TGC AGT ACA CC-3*) and G129 (5*-CCG TAG TCA CGG ATT ACG
CT-3*); f, G126 (5*-GGT TCT TAG CCC TGC TCA TC-3*) and 167 (5*-CCG TCG ACA TCG ATA ATA CG-3*); g, 166 (5*-AAG GAT CCG TCG ACA TCG
AT-3*) and G123 (5*-GAT TTA AGA TCT ACC AAC CCT G-3*); h, G71 (5*-AGC CCC AGA AAC CGA CGC CTA T-3*) and G82 (5*-GCC TCA GCC AGC
TTC ATC AG-3*); i, G137 (5*-ATG GAG GAC TGC AGT ACA CC-3*) and G128 (5*-GCA GTG CAT TAG CAC CAT CA-3*); j, G126 (5*-GGT TCT TAG
CCC TGC TCA TC-3*) and G130 (5*-ACC CCT TCA GAT CAC AGT GC-3*); k, G84 (5*-TAA TCC GTG ACT ACG GGC TG-3*) and 167 (5*-CCG TCG
ACA TCG ATA ATA CG-3*); l, G36 (5*-CGT CGC CCT TCA ATG TCT CTC T-3*) and G172 (5*-CTR TTG RCG AAG GGC ACA GC-3*); and m, G171
(5*-CGA AGA TCG ATG TGT GGA GT-3*) and G33 (5*-GGA GCC CAA GAC ACC AGG ACA AGG-3*). Ambiguity codes are Y  T or C; W  A or T;
R  A or G; D  G, A, or T; and H  A, T, or C.
heim, Germany). They were amplified by PCR with 5*UTR GCC GGC GTT GA-3* [nt 1467–1486]) and 413 (anti-
sense, 5*-CTG TTG ATG TGC CAG CTG CC-3* [nt 1593–primers (antisense) and 43-mer oligonucleotides containing
(T)17 or (A)17; these have been described as primer 171 or 1612]). Ten clones each were propagated from sera ob-
tained at two time points and sequenced.165 (Okamoto et al., 1992b). In order to determine the ex-
treme 3*-end sequences (regions f and k), extracted RNAs
Computer analysiswere tailed with poly(A) by poly(A) polymerase (TaKaRa Bio-
chemicals), converted to cDNA with the 43-mer oligonucleo- Sequence analysis was performed using ODEN Ver-
tide containing (T)17, and subjected to amplification by a sion 1.1.1 (National Institute of Genetics, Mishima, Japan)
single-sided PCR. and GENETYX Version 8.0 (Software Development Co.,
Amplification products were separated on gel electro- Ltd., Tokyo, Japan) programs. A phylogenetic tree of GBV-
phoresis and ligated into M13 phage vector, and cDNA C/HGV was constructed by the unweighted pair-group
clones representing each region were obtained by the method with arithmetic mean (Nei, 1987) and the neigh-
method described previously (Okamoto et al., 1992b). bor-joining method (Saitou and Nei, 1987).
Both plus and minus strands were sequenced by ALF
AutoRead DNA sequencing kit (Pharmacia LKB Biotech- RESULTS
nology, Uppsala, Sweden), and the consensus sequence
GSI85 and GSI93 isolates of GBV-C/HGVof three clones was adopted for each region.
The envelope genes of a GBV-C/HGV isolate (GSI96), GSI85 isolate recovered from a hemodialysis patient
recovered 2.8 years after the patient became infected soon after she contracted GBV-C/HGV infection and
with HCV, were sequenced over two regions (E1 and E2) GSI93 isolate obtained from her 8.4 years later (Fig. 1)
after amplification by PCR with primers deduced from were sequenced in full. They both consisted of 9391
conserved areas. bases and contained a long open reading frame (ORF)
spanning nt 553 to 9078 and coding for 2842 aa flanked
Sequencing the HVR of HCV
by putative 5*UTR (nt 1 to 552) and 3*UTR (nt 9079 to
9391) that did not have a poly(U) stretch or poly(A) tail.The patient contracted infection with HCV of genotype
II/1b. A sequence of 146 bp including HVR (nt 1467– Their ORF was divided into the C gene which was defec-
tive and encoded only 14 aa, putative E1 gene (190 aa)1612) was amplified by PCR with primers matching the
sequence of genotype II/1b, 412 (sense, 5*-CTA CTC TTC and E2 gene (387 aa), as well as NS2 (281 aa), NS3 (677
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genome and subgenomic regions. GSI93 was closest
to GT230 reported from Japan with an overall similarity
of 91.6% in nucleotide sequence and 98.6% in deduced
amino acid sequence. It was similar to the other four
genomes by 87.1 – 87.2% in nucleotide sequence and
96.6 – 97.6% in amino acid sequence. There were no
subgenomic regions that diverged much more than the
others. Although GSI93 was similar to HGV-R10291
only in 64.3% of amino acid sequence of the defective
C protein, only 14 amino acids for a C-gene product of
GSI93 were compared. A low similarity of 53.1% was
FIG. 3. Nucleotide differences between GSI85 and GSI93 isolates. observed in 3*UTR between GSI93 and prototype GBV-
Each genomic region is represented by a box followed by the sequence C; the comparison was made on merely 64 overlapping
position in parentheses. Silent mutations without amino acid changes
nucleotides.are indicated by short thin bars and missense mutations by long thick
These results indicated that GSI93 and GSI85 wouldbars.
belong to the same genotype of GBV-C/HGV tenta-
tively designated G3. In Fig. 4, a phylogenetic tree wasaa), NS4 (316 aa), NS5a (414 aa), and NS5b (563 aa)
constructed on seven GBV-C/HGV isolates, includingregions. These genes and regions were deduced by
GSI93 as well as GSI85 and the five reported, withincomparison with those of GB viruses A to C, HGV, and
an overlapping sequence of 8526 bases in the ORF; itHCV (Grakoui et al., 1993; Leary et al., 1996; Linnen et
corresponded to 91% of the longest genomic se-al., 1996; Muerhoff et al., 1995; Okamoto et al., 1997).
quence displayed by GT110. The tree was built by theGSI85 and GSI93 were different in 31 (0.3%) of the 9391
unweighted pair-group method with arithmetic meanbases. Based on this difference, the mutation rate of GBV-
(Nei, 1987), and revealed three genotypes of GBV-C/C/HGV was estimated to be 3.9 1 1004 base substitutions
HGV; it indicated GSI85 and GSI93 as members ofper site per year. Of 29 nucleotide conversions in the ORF,
genotype G3. The three genotypes were confirmed by5 (17%) were in the first letter, 3 (11%) in the second letter,
another tree constructed by the neighbor-joiningand the remaining 21 in the third letter; they induced only
method (Saitou and Nei, 1987).five amino acid changes. The distribution of missense and
silent mutations is shown in Fig. 3. They are scattered more
Changes in the amino acid sequence of the putativeor less evenly over various subgenomic areas. Remarkably,
envelope proteins of GBV-C/HGV and those in HVR ofmutations were not detected in 5*UTR and the 3*-terminal
co-infecting HCVtwo thirds of NS5b. They were not seen in 42 bases for the
defective C gene of GSI85 and GSI93, either. Only one of
Table 2 lists nucleotide mutations and induced aminothe five missense mutations was in the envelope genes
acid conversions within the E1 and E2 genes of GBV-C/(E2). In addition, there was one missense mutation in NS3,
HGV isolates during 8.4 years and an additional 2.8 yearstwo in NS5a, and one in NS5b.
after the patient became infected with HCV. Nine pointOf the 31 mutations observed in GSI93, 1 was detected
mutations occurred during 11.2 years with only twoalready in one of the three clones from GSI85. Since the
amino acid conversions in GBV-C/HGV, with an esti-mutation occurred in 3*UTR, it did not accompany an
mated mutation rate of 4.6 1 1004 nucleotide substitu-amino acid change. Another 2 nonsense mutations were
tions per site per year.found in two of the three clones in GSI93. The remaining
The sequence of 25 aa representing HVR is shown inclone had the same nucleotide as the one unanimously
Fig. 5 for HCV recovered at the first detection of HCVfound in all three clones from GSI85.
RNA and 2.8 years thereafter. Of 10 clones at the firstThe sequence and length of the extreme 3*-end was
detection, 5 (clones 1–5) had the identical sequence andthe same for all three clones from GSI93 and GSI85.
another (clone 6) differed from them in only 1 aa. TheThe extreme 5*-end in some clones was shorter than in
remaining 4 (clones 7–10) had the same sequence whichothers. The longest ones with nt 1 being T as in GT230
possessed 11–12 aa conversions from the others.and GT110 (Okamoto et al., 1997) were considered to
None of the clones 11–20, recovered 2.8 years later,cover the extreme 5*-end, and their sequences were
shared identical sequence of HVR with any clones fromadopted to represent GSI93 and GSI85.
the first detection of HCV. One of them (clone 11) was
Comparison of GSI85 and GSI93 isolates with five deduced to have evolved from clones 1–6, differing in
GBV-C/HGV genomes of which the full 3–4 aa, while all the others (clones 12–20) were from
sequence is known clones 7–10, differing in 7–9 aa. These amino acid con-
versions were induced by mutations in 3–4 nt and 8–11Table 1 compares GSI93 with the five reported GBV-
C/HGV genomes, as well as with GSI85, within the total nt, respectively. Thus a nucleotide substitution rate per
AID VY 8615 / 6a39$$$$42 05-22-97 21:30:52 vira AP: Virology
47MUTATION OF GB VIRUS C
TABLE 1
Percentage of Similarity of Nucleotide and Deduced Amino Acid Sequences within the Entire Genome and Subgenomic Regions
between GSI93 and Five Reported GB Virus C/Hepatitis G Virus Isolates as Well as GSI85a
GBV-C/HGV genotypes
G1 G2 G3
Genomic Nucleotides
region (amino acids) GBV-C HGV-PNF2161 HGV-R10291 GT110 GT230 GSI85
Entire 9103–9395 87.2 87.2 87.1 87.2 91.6 99.7
(2842–2933) (97.6) (96.6) (96.6) (97.6) (98.6) (99.8)
5*UTR 275–552 89.5 90.6 91.6 91.4 96.0 100
C 42–315 88.1 88.1 81.0 88.1 88.1 100
(14–105) (92.9) (92.9) (64.3) (92.9) (92.9) (100)
E1 570 89.1 85.4 85.1 84.7 90.5 99.6
(190) (97.9) (96.8) (95.8) (96.8) (98.4) (100)
E2 1161 86.5 85.4 85.1 85.0 92.3 99.7
(387) (96.4) (91.5) (94.3) (95.6) (97.7) (99.7)
NS2 843 84.7 83.9 85.8 83.4 89.2 99.5
(281) (97.5) (95.7) (96.8) (97.2) (98.2) (100)
NS3 2031 85.9 86.9 87.5 86.1 88.5 99.5
(677) (98.1) (98.5) (98.7) (99.0) (99.1) (99.9)
NS4 948 86.5 85.9 86.6 86.1 91.6 99.7
(316) (97.2) (95.9) (96.8) (96.8) (98.1) (100)
NS5a 1242 89.9 88.0 87.8 88.1 93.3 99.8
(414) (98.8) (96.9) (96.4) (97.3) (99.0) (99.5)
NS5b 1689–1692 88.8 88.3 88.2 89.6 92.2 99.9
(563–564) (97.3) (98.2) (98.0) (98.6) (99.1) (99.8)
3*UTR 64–315 53.1 96.2 91.8 96.2 98.4 99.4
a Genomic length and accession numbers of five reported isolates are prototype GBV-C, 9125 nt/U36380; HGV-PNF2161, 9392nt/U44402; HGV-
R10291, 9103 nt/U45966; GT110, 9395 nt/D90600; and GT230, 9390 nt/D90601.
site per year of 1.4 1 1002 to 5.2 1 1001 was estimated virus persistently infecting human beings. It transmits
parenterally, typically by transfusion and intravenousfor HVR of HCV during 2.8 years.
drug abuse (Aikawa et al., 1996; Linnen et al., 1996; Ma-
suko et al., 1996; Schmidt et al., 1996). GBV-C/HGV RNADISCUSSION
is detected frequently in patients with chronic hepatitis
GBV-C/HGV prevails across the world, infecting ap-
proximately 1–2% of apparently healthy blood donors in
TABLE 2the United States (Linnen et al., 1996), Japan (Masuko et
al., 1996), Italy (Fiordalisi et al., 1996), and China (Wang Nucleotide and Amino Acid Changes in the E1 Gene (nt 595–1164
[570 bp]) and E2 Gene (nt 1165–2325 [1161 bp]) of GB Virus C/et al., 1997). Hence, GBV-C/HGV would be a common
Hepatitis G Virus during 8.4 Years and an Additional 2.8 Years
Date tested
Nucleotide
position 6/11/1985 11/16/1993 9/16/1996
E1 gene
771 (aa 73) C (Pro) T (Pro) T (Pro)
864 (aa 104) G (Gly) G (Gly) A (Gly)
1077 (aa 175) G (Leu) A (Leu) A (Leu)
E2 gene
1239 (aa 229) T (Asn) C (Asn) C (Asn)
1510 (aa 320) A (Ser) A (Ser) G (Gly)
1557 (aa 335) C (Gly) T (Gly) T (Gly)
1903 (aa 451) A (Lys) G (Glu) G (Glu)FIG. 4. A phylogenetic tree of GB virus C/hepatitis G virus and three
proposed genotypes. The extreme 5*- and 3*-terminal sequences are 1953 (aa 467) T (Asn) C (Asn) C (Asn)
2304 (aa 584) G (Pro) G (Pro) A (Pro)not determined for two isolates (prototype GBV-C and HGV-R10291).
Sequence was compared within 8526 bases spanning nt 553–9078 in
the open reading frame, which have been determined for all of the a Mutated nucleotides and induced amino acid conversions are in
italic.seven GBV-C/HGV isolates.
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the C gene as in all reported isolates (Erker et al., 1996;
Leary et al., 1996; Linnen et al., 1996; Okamoto et al.,
1997), it is not certain if the estimate could be taken as
that of the complete GBV-C/HGV genome. The obtained
rate was less than that of hepatitis C virus (1.4–1.9 1
1003) (Ogata et al., 1991; Okamoto et al., 1992a). Muta-
tions for amino acid changes were induced by 38% of
nucleotide substitutions in HCV, at a rate much higher
than 16% found for GBV-C/HGV in the present study.
Like HCV, 5*UTR was most conserved during 8.4 years
without any mutations in the 552 nt constituting it. Al-
though 3*UTR was most variable, only 2 (0.6%) of 313 nt
changed. Within the coding region, conversions of 29 nt,
of which 5 induced amino acid changes, were scattered
over the entire genome. No subgenomic regions were
identified where mutations clustered. Remarkably, few
mutations occurred in the putative envelope genes (E1/
E2) with only one amino acid change.
In the HCV genome, there is an HVR in the N-terminus
of the E2 protein spanning 25–30 amino acids (Hijikata
et al., 1991; Ogata et al., 1991; Okamoto et al., 1992a;
Weiner et al., 1991). Since GBV-C/HGV is devoid of HVR,
FIG. 5. Amino acid sequences of the HVR of co-infecting HCV deter- it may use different means of escaping immune clear-
mined at the first recognition of infection and 2.8 years thereafter. ance by the host. It might be coated with lipoproteins,
as HCV is (Miyamoto et al., 1992; Prince et al., 1996; Sato
et al., 1993; Thomssen et al., 1992), or the other host
C, and is particularly common in patients on maintenance moieties to prevent surface proteins from binding with
hemodialysis, with prevalence rates ranging from 3.1 to antibodies. In support of this view, GBV-C/HGV is precipi-
58% (Alter, 1996; de Lamballerie et al., 1996; Masuko et tated by antibodies to human apolipoprotein A-I or apoli-
al., 1996; Tsuda et al., 1996; Wang et al., 1997). Although poprotein B, but hardly by antibodies to human IgG (Sato
most individuals infected with GBV-C/HGV have normal et al., 1996).
levels of serum transaminases, there are some patients It would have to be pointed out that the mutation
with fulminant or chronic hepatitis of a non-A to -E etiol- rate of GBV-C/HGV was estimated in a patient on main-
ogy who are infected with it (Fiordalisi et al., 1996; He- tenance hemodialysis who is known to have compro-
ringlake et al., 1996; Linnen et al., 1996; Yoshiba et al., mised immune responses (Descamps-Latscha and
1995). However, the site of replication or hepatitis-induc- Herbelin, 1993; Goldblum and Reed, 1980). However,
ing activity is, as yet, not clear for GBV-C/HGV. HVR of co-infecting HCV mutated with a nucleotide
Since GBV-C/HGV has not been propagated in cul- substitution per site per year of 1.4 1 1002 to 5.2 1
ture, the nucleotide sequences of viral isolates recov- 1001, which is comparable to that in immune-compe-
ered from infected individuals remain the only means tent individuals (Higashi et al., 1993; Taniguchi et al.,
of knowing its virological characteristics. Being an 1993). Since the hemodialysis patient we studied could
RNA virus that evolves rapidly (Holland et al., 1982), elicit antibody to HCV in due course, she would not
GBV-C/HGV is expected to have a high mutation rate. have been totally immunocompromised. The low muta-
We determined the entire sequence of two GBV-C/HGV tion rate observed in her, therefore, would not be as-
isolates recovered from a patient on maintenance he- cribable to compromised immune responses inherent
modialysis at an interval of 8.4 years, which were to hemodialysis patients.
named GSI85 and GSI93 isolates, respectively. Both
GSI85 and GSI93 had a genomic length of 9391 bases,
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